Forest Whistleblower Cases Settle for Over $300 Million
Nolan & Auerbach, P.A. announces another successful whistleblower recovery by their courageous clients, whose cases continue to return hundreds of millions of dollars to the…
Read More »Pharma 101 – Pharmaceutical Fraud
Pharmaceutical Fraud News & Insight form the Qui Tam and False Claims Act Perspective
Contact FormTag Archives: qui tam
Botox Whistleblower Case Settles for $600 Million
Pharmaceutical manufacturer Allergan, Inc. has agreed to pay $225 million to resolve civil allegations that it unlawfully promoted its drug Botox® Therapeutic for unapproved uses…
Read More »Out of the U.S. No Oversight Necessary?
Today the OIG posted "Challenges to FDA's Ability To Monitor and Inspect Foreign Clinical Trials" (OEI-01-08-00510). As all new investigational drugs and biologics must undergo…
Read More »Johnson & Johnson Subsidiaries to Pay More Than $81 Million to Resolve Allegations of Off-Label Promotion of Topamax
American pharmaceutical manufacturers Ortho-McNeil Pharmaceutical LLC and Ortho-McNeil-Janssen Pharmaceuticals Inc., both subsidiaries of Johnson & Johnson, have agreed to pay more than $81 million to…
Read More »AstraZeneca Agrees to $520 Million Settlement
Attorney General Eric Holder announced April 27, 2010, that AstraZeneca has agreed to pay $520 million to federal and state taxpayers to settle claims that…
Read More »FDA Warns Pfizer About Pediatric Trials of Geodon
On April 9th, the FDA issued a Warning Letter to Pfizer, Inc. concerning its conduct during a clinical trial for one of its prescription drugs…
Read More »Alpharma to Pay $42.5 Million to Resolve False Claims Act Allegations
Pharmaceutical manufacturer Alpharma, Inc. has agreed to pay $42.5 million to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug,…
Read More »Texas Hospital Group Pays $27.5 Million for False Claims Act Allegations
South Texas Health System, a McAllen, Texas-based hospital group, has agreed to pay the United States $27.5 million to settle claims that it violated the…
Read More »FDA’s Postmarketing Studies and Clinical Trials Draft Guidance Gets Supported By Public Citizen
In an October 13 letter to the FDA, the well respected consumer advocacy organization Public Citizen, gave a strong endorsement to the FDA Draft Guidance…
Read More »